Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BRIEF-Glycomimetics doses first patient in Phase 1 clinical trial of drug candidate GMI-1271 for multiple myeloma

By: Reuters: Company News
* Glycomimetics Doses First Patient In Phase 1 Clinical Trial Of Drug Candidate GMI-1271 for multiple myeloma
Related Stocks:
Glycomimetics Inc
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.